Stay current on changes and developments in corporate law with a wide variety of resources and tools.
By Fawn Johnson
Federal Trade Commission attorneys are looking for more cases to challenge companies’ anticompetitive conduct, an official said April 13.
“We’re open for business and we’re looking for cases,” said Bruce Hoffman, who heads the FTC’s division enforcing competition policy, at the American Bar Association’s annual antitrust conference in Washington. “My phone number is pretty easy to find.”
FTC has the authority to bring civil charges against companies that engage in unlawful anticompetitive conduct like unfair pricing or sham lawsuits to squeeze out rivals. The Justice Department can bring both civil claims and criminal charges against that type of conduct and has several ongoing investigations against price fixing cartels.
“It’s harder for us to find cases,” Hoffman said. “We don’t have wiretaps. We don’t have the FBI.”
Both the FTC and the DOJ investigate mergers on antitrust grounds, but lawsuits challenging those deals usually spring from the corporate filings about the transactions required by law. When it comes to cracking down on anticompetitive conduct, however, the agencies must rely on complaints from consumers or whistleblowers. The DOJ can offer leniency to the first company that comes forward to admit to a price-fixing cartel, but the FTC doesn’t have that ability.
The FTC has brought about twice as many cases involving mergers as on anticompetitive conduct. The agency challenged 23 mergers in fiscal 2017 and required remedies in 13 others, acting FTC chairman Maureen Ohlhausen said at the conference. It brought nine actions challenging conduct in the same year.
This year, the FTC so far has challenged 12 mergers on antitrust grounds and brought two other challenges based on conduct, she said.
The FTC has brought a number of cases in the pharmaceutical industry where brand-name drug companies use an array of tactics to delay generic competition for various drugs. For example, the agency charged generic drugmaker Impax Laboratories Inc. for allegedly accepting more than $100 million to delay its release of a generic version of an opioid pain medication. The brand drugmaker in that exchange, Endo Pharmaceuticals Inc., settled with the FTC in January 2017.
This week, the FTC also filed an administrative complaint against the Louisiana Real Estate Appraisers Board alleging that the group is unlawfully restraining price competition for home appraisals.
To contact the reporter on this story: Fawn Johnson in Washington at email@example.com
To contact the editor responsible for this story: Susan Jenkins at firstname.lastname@example.org
Copyright © 2018 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)